RxDoctor Payments Data

Daniel Mollin, MD

Internal Medicine · Raleigh, NCNPI 1588659577

Payments from drug & device makers

$1,876in general payments, 2019–2025

Across 119 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$488
  • Amgen$229
  • Lilly USA, LLC$213
  • Abbott$110
  • Daiichi Sankyo Inc.$108
  • Astellas Pharma US Inc$107
  • plus $621 from 20 others

What the payments were for

  • Food & beverage$1,876100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,876 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$167,547
Medicare patients
255
Services billed
7,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$137,947
TrulicityDulaglutide90$132,513
JardianceEmpagliflozin85$119,943
OzempicSemaglutide79$99,920
MounjaroTirzepatide45$54,942
XareltoRivaroxaban33$47,208
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$19,365
Breo ElliptaFluticasone/Vilanterol21$12,901
BelsomraSuvorexant26$11,061
Spiriva RespimatTiotropium Bromide14$9,572
VascepaIcosapent Ethyl14$9,461
Rosuvastatin Calcium468$7,274
Atorvastatin Calcium547$6,489
Tresiba Flextouch U-100Insulin Degludec15$6,244
Testosterone51$4,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$213$187,455135 claims
PfizerEliquis$63$137,94797 claims
Boehringer IngelheimJardiance, Spiriva Respimat$72$129,51599 claims
Novo NordiskOzempic$488$99,92079 claims
Johnson & JohnsonXarelto$49$47,20833 claims
GSKTrelegy Ellipta, Breo Ellipta$17$32,26639 claims
MerckBelsomra$42$11,06126 claims
AbbVieSynthroid$40$3,92455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →